Guest guest Posted October 2, 2009 Report Share Posted October 2, 2009 The popular diabetes drug sitagliptin (marketed as Januvia) may increase the risk of pancreatic cancer, according to study conducted by researchers from the University of California-Los Angeles and published in the journal Diabetes Read more at http://healtnhappyness.blogspot.com/ <http://healtnhappyness.blogspot.com/%20> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted October 2, 2009 Report Share Posted October 2, 2009 Not good. Do one thing every day that scares you. Eleanor Roosevelt From: berrgas <berrgas@...>Flu Sent: Friday, October 2, 2009 5:39:55 AMSubject: [Flu] Diabetes Drug Could Cause Pancreatic Cancer The popular diabetes drug sitagliptin (marketed as Januvia) may increase the risk of pancreatic cancer, according to study conducted by researchers from the University of California-Los Angeles and published in the journal Diabetes Read more at http://healtnhappyn ess.blogspot. com/ Quote Link to comment Share on other sites More sharing options...
Guest guest Posted October 5, 2009 Report Share Posted October 5, 2009 > > The popular diabetes drug sitagliptin (marketed as Januvia) may increase > the risk of pancreatic cancer Your typical run of the mill drugs aren't going to do much for chronic diseases, except likely to cause other serious problems long time. Probably one of the best ways to control diabetes and/or cure it would be a low-carbohydrate, ketogenic (high fat) diet, especially following Weston A Price principles. http://srv9.louhi.net/anttiheikkila.com/liitteet/173-7052-2-34.pdf A low-carbohydrate, ketogenic diet to treat type 2 diabetes Abstract Background: The low-carbohydrate, ketogenic diet (LCKD) may be effective for improving glycemia and reducing medications in patients with type 2 diabetes. Methods: From an outpatient clinic, we recruited 28 overweight participants with type 2 diabetes for a 16-week single-arm pilot diet intervention trial. We provided LCKD counseling, with an initial goal of <20 g carbohydrate/day, while reducing diabetes medication dosages at diet initiation. Participants returned every other week for measurements, counseling, and further medication adjustment. The primary outcome was hemoglobin A1c. Results: 21 of the 28 participants who were enrolled completed the study. The mean age was 56 years and BMI was 42.2 kg/m2. Hemoglobin A1c decreased by 16% from 7.5% to 6.3% from baseline to week 16. Diabetes medications were discontinued in 7 participants, reduced in 10 participants, and unchanged in 4 participants. The mean body weight decreased by 6.6% from 131.4 kg to 122.7 kg. Weight change at 16 weeks did not predict change in hemoglobin A1c. FASTING SERUM TRIGLYCERIDE DECREASED 42% while other serum lipid measurements did not change significantly. Conclusion: The LCKD improved glycemic control in patients with type 2 diabetes such that diabetes medications were discontinued or reduced in most participants. Because the LCKD can be VERY EFFECTIVE at lowering blood glucose, patients on diabetes medication who use this diet should be under close medical supervision or CAPABLE OF ADJUSTING THEIR MEDICATION. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.